Limit agreements between brand name and generic drug companies that delay the availability of lower cost medications.
One policy goal, tracked across every bill that has carried it.
What’s happening with Preserve Access to Affordable Generics and Biosimilars Act?
The Preserve Access to Affordable Generics and Biosimilars Act, known as S. 1096, has been on the Senate legislative calendar since April 9, 2025. The Senate must now hold a floor vote to advance the bill, but limited time for debate remains the primary constraint. While reaching the floor is a significant milestone that most bills fail to achieve, Senate leadership has not scheduled a vote for this proposal in the 14 months since it was reported.
Updated July 9, 2026 · Generated by AI. Always verify with official sources.
Where it stands
Now carried by Preserve Access to Affordable Generics and Biosimilars Act (S. 1096 (119th)) →
Legislative Progress
No action since April 2025
How we got here
Every bill that has carried this goal, oldest first.
Died with Congress · Jan 3, 2025
Died when the 118th Congress ended without final passage. Bills must be reintroduced under a new number to be revived.
Reintroduced · Jan 3, 2025
Reintroduced from S. 142 (118th), which died when its Congress ended.
S. 142 (118th) →
Vehicles
Who’s behind it
Amy Klobuchar (D-MN)Wrote and sponsored the current bill.